The PTCT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PTCT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PTCT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PTCT Detailed Price Forecast - CNN Money||View PTCT Detailed Summary - Google Finance|
|View PTCT Detailed Summary - Yahoo! Finance||View PTCT Stock Research & Analysis - Zacks.com|
|View PTCT Trends & Analysis - Trade-Ideas||View PTCT Major Holders - Barrons|
|View PTCT Call Transcripts - NASDAQ||View PTCT Breaking News & Analysis - Seeking Alpha|
|View PTCT Annual Report - CompanySpotlight.com||View PTCT OTC Short Report - OTCShortReport.com|
|View PTCT Fundamentals - TradeKing||View PTCT SEC Filings - Bar Chart|
|View Historical Prices for PTCT - The WSJ||View Performance/Total Return for PTCT - Morningstar|
|View the Analyst Estimates for PTCT - MarketWatch||View the Earnings History for PTCT - CNBC|
|View the PTCT Earnings - StockMarketWatch||View PTCT Buy or Sell Recommendations - MacroAxis|
|View the PTCT Bullish Patterns - American Bulls||View PTCT Short Pain Metrics - ShortPainBot.com|
|View PTCT Stock Mentions - StockTwits||View PTCT Stock Mentions - PennyStockTweets|
|View PTCT Stock Mentions - Twitter||View PTCT Investment Forum News - Investor Hub|
|View PTCT Stock Mentions - Yahoo! Message Board||View PTCT Stock Mentions - Seeking Alpha|
|View Insider Transactions for PTCT - SECform4.com||View Insider Transactions for PTCT - Insider Cow|
|View PTCT Major Holdings Summary - CNBC||View Insider Disclosure for PTCT - OTC Markets|
|View Insider Transactions for PTCT - Yahoo! Finance||View Institutional Holdings for PTCT - NASDAQ|
|View PTCT Stock Insight & Charts - FinViz.com||View PTCT Investment Charts - StockCharts.com|
|View PTCT Stock Overview & Charts - BarChart||View PTCT User Generated Charts - Trading View|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted on Tuesday October 23, 2018
SOUTH PLAINFIELD, N.J., Oct. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on October 17, 2018 it approved non-statutory stock options to purchase an aggregate of 68,700 shares of its common stock to 13 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on October 17, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). Eight of the stock option awards have an exercise price of $39.73 per share, the closing price of PTC's common stock on October 17, 2018, the date of the grant.
Market Trends Toward New Normal in PTC Therapeutics, AeroVironment, Autodesk, Coca-Cola Bottling Co. Consolidated, Akers Biosciences, and TEGNA — Emerging Consolidated Expectations, Analyst Ratings
Posted on Tuesday October 23, 2018
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results
Posted on Monday October 22, 2018
SOUTH PLAINFIELD, N.J. , Oct. 22, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2018 financial ...
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation
Posted on Saturday October 06, 2018
SOUTH PLAINFIELD, N.J., Oct. 6, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced preliminary data from the first international drug registry for Duchenne patients receiving Translarna™ (ataluren), underscoring the long-term clinical benefit of Translarna when used in routine clinical practice in delaying irreversible muscle loss in children with Duchenne caused by a nonsense mutation, when compared with published natural history. The data show that children and adolescents receiving Translarna in the real-world setting are continuing to walk years longer than untreated children, and are staying more physically able.